Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Preemptive share consolidation

<< Previous

Bullboard Posts

Next >>

Post by Greenviolinoon Feb 06, 2023 10:41pm

312 Views

Post# 35270891

Preemptive share consolidation

Do not expect great financial results when THTX annouces Year results. It might be better for THTX to voluntarily announce a share consolidation than having to live through the pain of a Nasdaq notice, and have traders control the share price. A share consolidation will also put the company in a better position for an inevitable new financing.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading